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Phosphorylated AKT (pAKT) is a major contributor to radioresistance in human cancers. The aim of this study was to investigate the
association of pAKT expression and radiation resistance in cervical cancer. A retrospective review was made of the records of 27
women who received primary radiation therapy due to locally advanced cervical cancer (LACC) with FIGO stage IIB–IVA. Nine
patients regarded as radiation resistant developed local recurrences with a median progression free interval of 9 months. Eighteen
patients did not show local recurrences, and were regarded as a radiation-sensitive group. Using pretreatment paraffin-embedded
tissues, we evaluated pAKT expression by immunohistochemistry. A significant association was found between the level of pAKT
expression and local recurrence. Immunohistochemical staining for pAKT was significantly more frequent in the radiation-resistant
than in the radiation-sensitive group (P¼0.004). The mean progression-free survival was 86 months for patients with pAKT-negative
staining (19 cases) and 44 months for patients with pAKT-positive expression (eight cases) (P¼0.008). These results suggest that
signalling from phosphatidylinositide 3-kinase/pAKT can lead to radiation resistance, and that evaluation of pAKT may be a prognostic
marker for response to radiotherapy in LACC.
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Cervical cancer is still the second most common cancer in women
worldwide, despite the existence of effective screening methods
(Waggoner, 2003). Radiation therapy can be used to treat all stages
of cervical cancer, but in early-stage disease, it is usually reserved
for medically unfit patients. Including adjuvant radiotherapy
following surgery, which is used in approximately 1
3 of patients
with stage IB disease, radiotherapy is the most commonly used
treatment modality for 460% of cases of cervical cancer (Chung
et al, 2005). The most significant change in the standard radiation
treatment of cervical cancer has been cisplatin-containing
concurrent chemotherapy with radiation for patients with
locoregionally advanced disease (Keys et al, 1999; Morris et al,
1999; Rose et al, 1999). Despite the fact that concurrent
chemoradiation demonstrated a marked improvement in pelvic
disease control and survival, the resistance of tumour cells to
radiation remains a major therapeutic problem. Although tumour
size and international federation of gynaecology and obstetrics
(FIGO) stage may serve successfully as markers for responsiveness
to radiotherapy, they are not likely to fully account for the
observed variability. New markers are needed to predict more
accurately the response to radiotherapy of an individual patient.
The phosphatidylinositide 3-kinase (PI3K)/AKT-signalling path-
way has recently been demonstrated to be a major survival signal
in cancer cells. Phosphatidylinositide 3-kinase/AKT pathway has
epidermal growth factor receptor (EGFR) and insulin-like growth
factor signalling as upstreams, and it crosstalks with RAS/MAP
kinase pathway. Indeed, the role of this pathway in tumorigenesis
has been extensively investigated and altered expression or
mutations of many components of this pathway have been
implicated in human cancer (Vivanco and Sawyers, 2002).
Phosphorylated and activated AKT leads to inhibition of apoptosis
by inactivating several proapoptotic proteins, including BAD,
BAX, and caspase 9, and also by inducing the expression of
antiapoptotic proteins such as BCL2, BCLXL, FLIP, cIAP2, XIAP,
and survivins (Mitsiades et al, 2002). Recent studies have shown
that the PI3K/AKT cell survival pathway is activated post ionising
radiation and UV radiation. Phosphatidylinositide 3-kinase/AKT-
mediated survival pathways may fight imminent cell death and
possibly induce insensitivity of tumour cells to radiation therapy
(Zhan and Han, 2004). The increased expression of pAKT has been
linked to decreased radiation responsiveness in various cancers,
including head and neck squamous cell carcinoma, lung carcino-
ma, glioblastoma, and prostate and breast cancer (Gupta et al,
2002; Blackhall et al, 2003; Choe et al, 2003; Dent et al, 2003; Gupta
et al, 2003; Liao et al, 2003; Vijapurkar et al, 2003; Schmitz et al,
2004). Therefore, the status of AKT may serve as a prognostic
marker and the inhibition of PI3K/AKT-signalling pathway may
provide an additional targeted approach to improve the outcome
of radiotherapy.
With respect to cervical cancer, there have been a few studies
about PI3K/AKT-signalling and related pathways. Epidermal
growth factor receptor expression is higher in cervical intraepithe-
lial neoplasia and cervical cancers than in normal controls (Mathur
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set al, 2000). Overexpression of the EGFR is associated with a
poorer prognosis in patients with cervical cancer (Kersemaekers
et al, 1999). Preclinical studies have shown that radiotherapy with
a combination of antibodies to EGFR can improve local tumour
control (Pillai et al, 1998; Nasu et al, 2001). Epidermal growth
factor receptor signal functions through the activation of AKT.
Phosphoinositide-3-kinase catalytic alpha, involved in the PI3K/
AKT-signalling pathway, is known to be an oncogene associated
with cervical cancer (Ma et al, 2000). In addition, the PI3K catalytic
subunit is amplified in cervical cancer, and the inhibition of PI3K
by LY294002 radiosensitises human cervical cancer cell lines (Lee
et al, 2006). Therefore, we thought it would be worthwhile to
investigate the components of PI3K/AKT pathway in cervical
cancer.
In this study, we evaluate activated AKT using immunohisto-
chemistry in patients with locally advanced cervical cancer
(LACC), and have correlated pAKT staining with local recurrence
following radiation in the patients studied. We suggest that
activated AKT may lead to radiation resistance, and that PI3K/
pAKT signalling may constitute a therapeutic target in cervical
cancer.
MATERIALS AND METHODS
Patient selection
Between 1994 and 2001, a total of 119 patients with LACC stage
IIB–IVA were treated by primary radiotherapy in the Department
of Radiation Oncology, Samsung Medical Center, Sungkyunkwan
University School of Medicine. From among them, 19 cases
(15.9%) of pelvic recurrence were identified. Owing to the limited
availability of tissue block specimens, we could not use 10 tissue
blocks among 19 cases with local recurrence: the tissue biopsy was
performed at outside clinics in five cases; and the biopsy was
performed at out institution but tissue blocks were not available in
four cases; and the size of the tissue block was too small to study in
one case. We tried to match cases and controls (nine cases and 18
controls). Therefore, we studied 27 patients whose preradiation
cervical biopsy specimens were available. Study records were
reviewed according to institutional review board guidelines. Slides
were prepared from the paraffin-embedded tissue blocks from
these 27 patients. Included were 18 patients who showed no local
recurrence until at least 3 years after treatment, except for one
patient who died 14 months after pelvic radiotherapy due to
paraaortic lymph node recurrence without evidence of pelvic
disease. This comprised the radiation-sensitive group. The
remaining nine cases with punch biopsy specimen availability
came from the group of 19 who had pelvic recurrence, the
radiation-resistant group.
We measured the tumour volume on MRI. The tumour volume
was defined as volume calculated by the following formula:
0.524 largest anteroposterior dimension largest width dimen-
sion largest craniocaudal dimension (Campbell et al, 1982).
All of these patients were given external beam radiotherapy
(EBRT) as well as high-dose rate (HDR) intracavitary brachyther-
apy (Lee et al, 2004; Nakano et al, 2005). The whole pelvis total
dose was 5040Gy with 1.8Gy of daily fraction, administered five
times a week. High-dose rate brachytherapy was started 4–5 weeks
after the initiation of the EBRT. The dose of HDR brachytherapy
was 24Gy at point A, with 4Gy per fraction twice a week for 3
weeks.
Immunohistochemical staining
Immunohistochemical staining was performed under the standard,
avidin–biotin complex–peroxidase method (DakoCytomation,
Denmark) using formalin-fixed, paraffin-embedded tissue sec-
tions. Four-mm-thick tissue sections were mounted on poly-L-
lysine-coated glass slides and dried at 37.81C overnight. The
sections were deparaffinised in xylene, washed in graded ethanol,
and finally washed in phosphate-buffered saline (pH 7.4). To
increase specificity and sensitivity, samples were pretreated with
target retrieval citrate buffer (pH 6.0, S 2367; DakoCytomation,
Denmark), in a microwave for 20min. The endogenous peroxidase
activity was blocked with 3% H2O2 for 15min and the samples
were preincubated with a protein-blocking solution for 10min.
Slides were stained with the IHC-specific phosphorylated Ser 473
Akt antibody (1:40 dilution, Cell Signalling TECHNOLOGY
s Inc.,
Beverly, MA, USA) at 41C overnight in humid chamber, as
described by Zhou et al (2000). Slides were washed three times in
phosphate-buffered saline and then incubated with a biotinylated
goat anti-rabbit secondary antibody for 30min at room tempera-
ture. Antigen–antibody complexes were detected with the avidin–
biotin complex–peroxidase method, using diamminobenzidine as
a chromogen substrate (Vectastain ABC-kit, Vector Laboratories,
Burlingame, CA, USA), according to the manufacturer’s protocol.
Tissue sections were lightly counterstained with haematoxylin and
then examined by light microscopy. One dedicated gynaecologic
pathologist (SYS) and one gynaecologic oncologist (JWL) reviewed
the blinded slides and evaluated the immunohistochemical data,
independently. The agreement between the two reviewers was very
strong. The staining was scored on a scale from 0 to 3þ as follows:
0, no staining; 1þ, o50% with weak intensity; 2þ, more than
50% with weak or moderate intensity; 3þ, more than 50% with
strong intensity. For statistical analysis of survival curve, we
classified the pAKT expression of score 0 or 1þ as pAKT negative,
score 2þ or 3þ as pAKT positive. Because keratinised tumour
cells often caused artefactual staining, these keratinised areas were
excluded from the analysis (Gupta et al, 2002).
Statistical analysis
Statistical calculations were carried out using SPSS for Windows
version 13.0 (SPSS Inc., Chicago, IL, USA). For continuous
variables, the Mann–Whitney U-test was used. For categorical
variables, linear by linear association was performed. To evaluate
the relationship of pAKT staining to progression-free survival
(PFS), we calculated Kaplan–Meier curves in conjunction with the
log-rank test.
RESULTS
Patient characteristics are described in Table 1. The median follow-
up for the patients studied was 54 months. At the time of analysis,
eight patients had died. One of eight died 96 months after
radiotherapy, of causes unrelated to cervical cancer. One patient in
the radiation-sensitive group developed paraaortic lymph node
recurrence 10 months after pelvic radiotherapy and died 4 months
later. There were no significant differences in age, cell type,
histologic grade, tumour size, overall duration of therapy, and
FIGO stage between the two groups.
Immunohistochemical expression of pAKT was examined in 27
cervical squamous cell carcinomas (18 in the radiation-sensitive
and nine in the radiation-resistant group). The results are
summarised in Table 2. There was no strong staining (3þ)o f
pAKT in the radiation-sensitive group. There was no case without
pAKT staining in the radiation-resistant group. Expression of
pAKT was significantly more frequent in the radiation-resistant
group, compared to the radiation-sensitive group (P¼0.004).
Figure 1 illustrates the pAKT staining. It should be noted that
false-positive staining was noted on keratin both in keratin pearls
and in the epithelium, but this staining was excluded from
evaluation.
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sThe PFS of all the patients studied was analysed based upon
pAKT expression. The mean PFS was 86 for patients with pAKT-
negative staining and 44 months for patients with pAKT-positive
expression. The patients with pAKT-positive expression showed
the poorer prognosis (P¼0.008) (Figure 2).
DISCUSSION
The results of this study evaluating histological pAKT expression
prior to treatment in cervical cancer patients treated with primary
radiotherapy show a significant association between pAKT
expression and local recurrence. In addition, univariate survival
analysis showed pAKT-positive tissue was associated with poor
PFS following radiotherapy.
There is only one other study of AKT expression in cervical
cancer treated with radiotherapy (Lee et al, 2005). Interestingly,
however, Lee et al suggest the opposite conclusion: decreased
pAKT correlated with increased disease progression, although it
was difficult to determine whether this finding is based on
pretreatment patient samples. Both studies utilised immunohisto-
chemical staining using the same antibody. The difference between
the two seems to be the way to interpret the data. We cannot
explain these discrepant results, exactly. Nonetheless, we made a
discussion on the results from the Lee’s paper on the following
points: The finding that diminished pAKT expression was
significant for diminished overall survival (OS) is not a common
characteristic of pAKT in human cancer. Also, their conclusion
that only increased HER2 expression associated with improved
OS is quite an opposite conclusion to the previous paper (Nakano
et al, 1997). In addition, Lee suggested that ‘PI3K inhibition
radiosensitises cervix cancer’ in his recent publication (Lee et al,
2006).
Radiation produces highly reactive free radicals, such as reactive
oxygen species, which in turn interact with DNA to produce strand
breaks that interfere with the cell’s ability to reproduce. These
molecules also function as intracellular messengers involved in the
production of cytokines, growth factors, gene transcription, and
apoptosis (Sen and Packer, 1996; Lander, 1997). Activated AKT can
be induced by radiation, and it also may decrease imminent cell
death or apoptosis from radiation injury. The mechanisms by
which PI3K/AKT signalling functions in radiation responses may
include regulation of mitochondrial proteins, transcription factors,
translation machinery, and cell-cycle progression (Testa and
Bellacosa, 2001; Zhan and Han, 2004).
There are three types of AKT (AKT-1, -2, and -3) in human
tissues. However, the exact role of each has not been established in
cervical cancer. Owing to the advent of high-quality phosphory-
lated pan-AKT serine 473 antibodies, it is possible to measure the
phosphorylation of all three AKT family members using immuno-
histochemistry to examine AKT activity (Malik et al, 2002). We
also evaluated all three AKT using phosphorylated pan-AKT
antibody.
Clinical staging fails to detect extension of disease to the
paraaortic lymph nodes in approximately 17% of patients with
stage IIB cervical carcinoma, and in 29% of those with stage III
disease. Such patients have ‘geographic’ treatment failure if
standard radiation therapy ports are used (Hacker, 1988). Since
we did not perform routine paraaortic sampling nor extended-field
radiation in patients with cervical cancer, it is appropriate to
define patients with local failure after primary radiation therapy,
but not with distant failure only, as the ‘radiation-resistant’ group.
To compare PFS according to pAKT staining, we grouped cancer
tissues with no or 1þ staining into ‘pAKT-negative’, and 2þ or
3þ staining into ‘pAKT-positive’. The pattern of staining was
mostly cytoplasmic. Since the epithelial layer in some normal
cervical tissues showed weak cytoplasmic staining for pAKT, it is
appropriate to group both no staining and 1þ staining into ‘pAKT
negative’.
We reviewed the clinical factors relevant to radiation in four
pAKT-negative, radiation-resistant patients. Although all had low-
stage diseases (stage IIB), they tended to be older in age, have
greater tumour volume, higher grade, and shorter overall
treatment duration than five pAKT-positive, radiation-resistant
patients (Table 3). However, all these data showed no statistical
significance.
The present retrospective study has a few limitations. Because of
the low rate of cervical cancer with local recurrence after
radiotherapy and a rarity of pretreatment tissue, the number of
patients studied was small. Therefore, it is not easy to generalise
these results into the larger population of patients with cervical
cancer due to selection bias. We could not but limit the association
of the pAKT expression with cervical carcinoma as descriptive
Table 1 Patient characteristics
Characteristics
Radiation
sensitive
(n¼18)
Radiation
resistant
(n¼9) P-value
Median age, years (range) 65 (38–80) 59 (36–73) 0.410
Stage 0.633
IIB 11 (61%) 5(56%)
IIIB 7 (39%) 3 (33%)
IVA 1 (11%)
Cell type 1.00
Squamous cell 18 (100%) 9 (100%)
Histologic grade 0.198
I 6 (33%) 1 (11%)
II 10 (56%) 6 (67%)
III 2 (11%) 2 (22%)
Median tumour volume, cm
3
(range)
19.1 (0.79–89.9) 31.4 (7.86–81.9) 0.777
Median OTT, days (range) 54.5 (41–77) 56 (50–74) 0.290
Median PFS, months (range) 70 (10–104) 9.0 (5–62) o0.001
Recurrence
Local 0 9
Distant 1 1
a
Current status
NED 16 0
AWD 0 3
DOD 1 6
DWOD 1 0
OTT: overall treatment time; PFS: progression-free survival; NED: no evidence of
disease; AWD: alive with disease; DOD: dead of disease; DWOD: dead without
disease.
aOne patient had local and paraaortic lymph node recurrence at the same
time.
Table 2 Results of immunohistochemical analysis for pAKT in radiation-
sensitive and radiation-resistant cervical cancer tissues
pAKT staining
Negative (n¼19) Positive (n¼8)
0 1+ 2+ 3+ Total (N¼27)
Radiation-sensitive 7 8 3 0 18
Radiation-resistant 0 4 2 3 9
The expression of pAKT was significantly more frequent in radiation-resistant than
radiation-sensitive tissues (P¼0.004).
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srather than drawing a definitive conclusion based on statistical
analyses. We hope that our observation from this small series
would potentially prompt large, multi-institutional investigations.
Small sample size also made it difficult to perform multivariate
analyses in order to evaluate the pAKT expression as a predictor
for radiation response. A criticism of this study would be its
reliance on a single readout of Akt pathway activation. An
additional demonstration of frequent phosphorylation of other
pathway components, such as the downstream effectors mTOR
and FOXO, or downregulation of phosphatase and tensin, will be
needed.
In this study, we investigated whether pAKT expression
measured in biopsy specimens of pretreatment human cervical
cancers is associated with the response to radiation. If the PI3K/
AKT pathway mediates radiation resistance in cervical cancer, then
examination of activity of this pathway might predict the
recurrence rate in patients with cervical cancer treated similarly
with primary radiation. We found pretreatment pAKT expression
to be significantly associated with local control of the cancer and
with PFS. To more clearly evaluate the predictive role of pAKT to
the radiation response in patients with cervical cancer, further
studies with larger sample size will be performed.
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